Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CXKJ 8k
On August 25, 2022, the Company’s Board of Directors approved a certificate of amendment to its Articles of Incorporation in order to effectuate a 10 for 1 forward stock split (the “Stock Split”) of its outstanding Common Stock. The Board of Directors established a record date of September 16, 2022, for the Stock Split. The Company will file a Certificate of Change with the Secretary of State of Nevada on approximately September 16, 2022. The 10:1 forward split will be effective at 12:01 AM (Eastern Daylight time) on September 17, 2022. Our common stock will begin trading on a post-split basis at the opening of trading on the US markets on September 19, 2022.UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 25, 2022
KUN PENG INTERNATIONAL LTD.
Formerly known as CX Network Group Inc.
Nevada 333-169805 EIN 32-0538640
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
1F, Building 3, No. 1001, Huihe South Street
Banbidian Village
Gaobeidian Town, Chaoyang District
Beijing, PRC
100025
(Address of Principal Executive Offices) (Zip Code)
+86 -1087227012
Registrant’s Telephone Number, Including Area Code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Not Applicable
TABLE OF CONTENTS
Item No. Description of Item Page No.
Item 5. 02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
3
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. 3
Item 5.07
Submission of Matters to a Vote of Security Holders
3
Item 7.01 Regulation FD Disclosure 4
Item 9.01 Financial Statements and Exhibits 5
2
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On August 25, 2022, a Certificate of Amendment was approved by joint written consent of the Board of Directors and the Majority Consenting Stockholder holding 55.5% of the total issued and outstanding shares of common stock of Kun Peng International Ltd., a Nevada corporation (the “Corporation”) to increase the authorized number of shares of the Corporation’s $0.0001 par value common stock (the “Common Stock”) from 200,000,000 shares to 1,000,000,000 shares of Common Stock.
Thus, upon the filing of the Certificate of Amendment, the Corporation’s authorized capital shall consist of: (i) 1,000,000,000 shares of par value $0.0001 Common Stock; and (ii) 10,000,000 shares of par value $0.0001 Preferred Stock, which may be issued in series and with such voting powers, designations, preferences, limitations, restrictions, and relative rights as the Board of Directors shall determine in its sole discretion.
A copy of the Certificate of Amendment is attached as an exhibit to the Joint Written Consent of the Board of Directors and Majority Consenting Stockholders of the Corporation as Exhibit 99.1 to this Form 8-K. The amendment to the Corporation’s Articles of Incorporation is effective as of the date of acceptance by the Secretary of State of the State of Nevada.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On August 25, 2022, a majority of the Corporation’s shareholders entitled to vote through a written consent, approved the increase in the authorized number of shares of Common Stock and the filing of the Certificate of Amendment to the Articles of Incorporation so that the Corporation shall have 1,010,000,000 authorized shares of capital stock with 1,000,000,000 shares designed as $0.0001 par value Common Stock and 10,000,000 designated as $0.0001 par value Preferred Stock.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Two Non-Executive Independent Directors
On August 25, 2022, the Board of Directors appointed Ms. Lili Zhang and Ms. Lingya Jia as non-executive independent members of the Board of Directors of the Corporation to serve until the next meeting of the Board of Directors of the Corporation following the Annual Shareholder’s meeting or until her respective successor shall have been elected.
3
Biographies
Ms. Lili Zhang is a non-executive independent member of the Board of Directors. Ms. Zhang has thirteen years of experience in high-end international financial planning industry developing an expertise in private placement, asset allocation, trust, insurance, and other industries. Currently, Ms. Zhang is employed as an assistant to the president of America Great Health co-managing important issues.
From 2014 to 2020, Ms. Zhang was employed for a period of 7 years as a senior financial manager in Zhongtian Jiahua Wealth Management Co. Ltd. and for a period of 3 years with Wells Fargo Chase Asset Management Co. Ltd., providing a full range of asset allocation, trust, asset management, private equity, equity investment, overseas immigration, Hong Kong insurance and other investment products for high-end customers. From 2012 to 2014, Ms. Zhang served as a VIP account manager in DBS Beijing Branch providing comprehensive asset allocation consulting for middle and high-end clients and whose performance ranked first in Beijing Branch and third in Northern region in China. From 2009 to 2012, Ms. Zhang was employed at the Beijing Branch of ICBC AXA Life Insurance Co., LTD. (ICB-AXA) where her duties included assisting the company in actively fulfilling the business targets established by AXA Holding Company in France and providing customized health protection and asset preservation planning services for clients.
Ms. Zhang graduated from Nankai University in the People’s Republic of China with a bachelor’s degree in 2007. She currently has permanent residency in the United States and is also qualified as an insurance agent and fund practitioner in China.
Ms. Lingya Jia is a non-executive independent member of the Board of Directors. Ms. Jia has an extensive background in international business relations and brand crisis management with a wide range of experience in the capital markets, business researching and marketing communication advertisements.
From 2018 to 2021, Ms. Jia served as the brand product marketing director of CV China, an influential VC/PE media organization in the People’s Republic of China, where she was responsible for several listed companies in communication training and business plan guidance, capital market analysis reports and other brands’ external cooperation. From 2016 to 2018, Ms. Jia worked at Edelman International PR (PRC) Co. Ltd., the branch of a large independent communications group in the United States, as the account executive of market communication, branding promotion and analysis for tech clients, including Tencent Ads BU, a smartphone vendor Vivo and other international brands.
Ms. Jia graduated from University of Bath (UK) with a Master’s in Arts with International Relations studies in 2015 and Shanghai International Studies University with a Bachelor’s in Management. During this time, Ms. Jia also obtained related qualifications of fund and securities in the People’s Republic of China.
Item 7.01. Regulation FD Disclosure
On August 25, 2022, the Company’s Board of Directors approved a certificate of amendment to its Articles of Incorporation in order to effectuate a 10 for 1 forward stock split (the “Stock Split”) of its outstanding Common Stock. The Board of Directors established a record date of September 16, 2022, for the Stock Split. The Company will file a Certificate of Change with the Secretary of State of Nevada on approximately September 16, 2022. The 10:1 forward split will be effective at 12:01 AM (Eastern Daylight time) on September 17, 2022. Our common stock will begin trading on a post-split basis at the opening of trading on the US markets on September 19, 2022.
4
Each shareholder of record as of September 16, 2022 (the “Record Date) will receive ten (10) shares of Common Stock for each one share (1) of Common Stock held as of the record date. No fractional shares of common stock will be issued in connection with the Stock Split. Instead, all shares will be rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of authorized shares of common stock of the Company was increased as the shares of outstanding common stock were increased in the Stock Split from 200,000,000 authorized shares to 1,000,000,000 authorized shares of Common Stock.
The Company’s transfer agent is Transhare Corp., 15500 Roosevelt Blvd., Suite 301, Clearwater, Florida 33760, telephone: 727.289.0010.
See Press Release attached as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are being filed with this Current Report on Form 8-K:
Exhibit
Number
Description
3.1 Certificate of Amendment to the Articles of Incorporation of Kun Peng International Ltd.*
99.1
Joint Written Consent of the Board of Directors and Majority Consenting Stockholder of Kun Peng International Ltd. approving the increase of its authorized capital structure from 200,000,000 shares of $0.0001 par value common stock to 1,000,000,000 shares of $0.0001 par value common stock, and retaining the previously authorized $0.0001 par value preferred shares, which may be issued in series and with such voting powers, designation, preferences, limitations, restrictions and relative rights as the Board of Directors may determine in its sole discretion. **
99.2 Kun Peng International Ltd Press Release dated September 5, 2022. *
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
* To be filed by amendment
** Filed herewith
5
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.
KUN PENG INTERNATIONAL LTD.
By: /s/ ZHUANG Richun
Zhuang Richun, Chief Executive Officer
Date: September 5, 2022
6
Exhibit 99.1
USNU 8k
https://www.otcmarkets.com/filing/html?id=15270064&guid=vI5wkpLZGSa7nth
Item 1.01.
Entry into a Material Definitive Agreement.
U.S. NeuroSurgical, Inc.(“USN”), a wholly-owned subsidiary of the registrant, U.S. NeuroSurgical Holdings, Inc. (“USNU” or the “Company”), entered into a Share Exchange Agreement and Plan of Reorganization dated as of October 1, 2021 (the “Share Exchange Agreement”) with Elite Health Plan, Inc., a California corporation (“Elite Health”) and its shareholders. Under the terms of the Share Exchange Agreement, USN will acquire all of the outstanding shares of capital stock of Elite Health and, in exchange therefor, the former holders of Elite Health will receive newly-issued shares of USN, which when issued will represent 15% of the shares of USN after the transaction.
The transaction with Elite Health is structured as an investment by Elite Health shareholders in USN, a subsidiary of the Company, and as such will not have an immediate effect on the percentage ownership of the shareholders of USNU. However, USNU’s interest in USN, which currently holds substantially all of the interest in USNU’s businesses and operations, will be diluted by 15% as a result of the issuance of the new USN shares to the former holders of Elite Health. In addition, the Company agreed with the former Elite Health shareholders that if there is no trading market for the shares of USN after six months from the closing of the transaction, such holders may request that USNU take steps that would give such holders access to the public trading market, which could be accomplished at the Company’s election through an exchange of such holders’ shares for USNU shares.
The above description of the Share Exchange Agreement does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Share Exchange Agreement, which is attached hereto as Exhibit 2.1 and is incorporated herein by reference.
Elite Health is a private company with a limited operating history. It was formed in 2017 with the purpose of establishing a managed care organization that will operate as a Medicare Advantage plan for seniors. It is expected that Elite Health will operate in California, initially San Bernadino, Riverside, and Orange Counties, with the objective of addressing the growing number of Medicare eligible seniors in those markets. Because of the collective experience of its founders and affiliates as physicians, software executives, and health plan administrators, we believe that Elite Health will be positioned to bring to southern California a comprehensive and cost-effective solution for these communities.
Elite Health is in the process of applying for a Knox Keene license to operate a Medicare Advantage plan in California, and has taken preliminary steps toward identifying a network of providers who are well-versed in the healthcare needs of seniors in the communities in which they practice. Elite Health founders and affiliates also have considerable experience with healthcare record based software and will endeavor to utilize the latest advances in information systems, including AI and data analytics, in its processes to enhance each patient experience and control medical costs.
The Company and Elite Health understand that the keys to success with a managed care organization are delivering comprehensive patient care and containing costs. In addition to developing a plan to obtain necessary approvals, gaining access to a competent network of providers and enrolling a critical level of subscribers, it will be necessary for the plan to provide high quality patient care efficiently and cost effectively. There can be no assurance that the Company and Elite Health will be effective in doing so.
2
Company filed for reinstatement
https://esos.nv.gov/EntitySearch/BusinessFilingHistory?businessid=649967
VUME https://otce.finra.org/otce/dailyList
Summary
Date/Time Event Type Eff/Ex Date/Time Symbol Issue Name Market
06/17/2021 13:02:13 Name/Symbol/CUSIP Change 06/18/2021 00:00:00 VUME VuMee Inc. Common Stock Other OTC
Details
Previous Value Current Value
Symbol VUME QMEI
Issue Name VuMee Inc. Common Stock QUANTUM METAL EXCHANGE INC Common Stock
Class
Maturity Date
Market Category Other OTC Other OTC
Unit of Trade 100 100
Regulatory Transaction Fee Flag Yes Yes
Current Value
Daily List Date/Time 06/17/2021 13:02:13
Event Type Name/Symbol/CUSIP Change
Effective/Ex Date/Time 06/18/2021 00:00:00
Subject to Corporate Action
Offering Type No Restrictions
Daily List Comment
VASO
https://www.otcmarkets.com/stock/VASO/news/story?e&id=1884845
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2020
The Company Reports Improved Profitability Despite Pandemic
PLAINVIEW, NY / ACCESSWIRE / May 4, 2021 / Vaso Corporation ("Vaso") (OTC PINK:VASO) today reported its operating results for the three months and year ended December 31, 2020.
"The Company was able to conclude a profitable year in 2020 as it experienced an unprecedented impact of the economic shutdown due to the pandemic," commented Dr. Jun Ma, President and CEO of the Company. "Specifically, net income for fiscal year 2020 was $358 thousand, compared to a net loss of $382 thousand in the prior year, although revenue for the year decreased by $5.7 million to $69.9 million."
"The much-improved profitability was primarily the result of significant cost reductions. Selling, general and administrative costs went down by $4.0 million, or 9.7%, in 2020 when compared to 2019," Dr. Ma continued. "In addition, the Company generated $5.9 million from operating activities in the year 2020 and its cash position remains strong."
"As the country starts to get back to normalcy, we'll continue to exercise our diligence in executing our strategy and look to further improve performance of all our business units," concluded Dr. Ma.
The following financial results for the three and twelve months ended December 31, 2019 have been revised for the correction of errors.
Financial Results for Three Months Ended December 31, 2020
For the three months ended December 31, 2020, revenue decreased by 21.2% to $18.7 million from $23.7 million for the same period of 2019, due primarily to the decrease of $4.1 million, or 36.6%, in revenue in our professional sales service segment as the result of lower deliveries by our partner of underlying equipment during the quarter. Revenue in our IT segment decreased 3.4%, to $10.9 million in the fourth quarter 2020, compared to the same quarter of 2019, while our equipment segment revenue decreased 44.5% to $614 thousand from $1.1 million for the fourth quarter of 2019, due to the deconsolidation of EECP business as the result of the sale of equity in the EECP business early in the year, offset by an increase in sales in our Biox products.
Gross profit for the fourth quarter of 2020 decreased by 22.5% to $11.1 million, compared with a gross profit of $14.3 million for the same quarter of 2019. This decrease was primarily the result of the decrease in revenue in the professional sales service and IT segments.
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2020 decreased by 14.1% to $9.6 million, compared to $11.1 million for the fourth quarter of 2019. The decrease was primarily attributable to a decrease in personnel costs in the IT segment and other cost reductions. SG&A expenses were 51.2% and 47.0% of revenue in the fourth quarter of 2020 and 2019, respectively.
Net income for the three months ended December 31, 2020 was $1.2 million, compared with a net income of $2.7 million for the three months ended December 31, 2019.
Financial Results for Year Ended December 31, 2020
For the year ended December 31, 2020, revenue decreased by $5.7 million or 7.5% to $69.9 million when compared with $75.5 million for the year 2019. Revenue in our IT segment decreased 3.5% to $43.9 million for the year 2020, from 2019 revenue of $45.5 million, primarily due to a decrease of revenue in the healthcare IT business. Commission revenues in our professional sales service segment decreased by 12.8% to $22.9 million in the year 2020, compared to $26.2 million in 2019. The decrease was the result of lower equipment deliveries by our partner and lower blended commission rates for the equipment delivered during the year. Equipment segment revenue for the year 2020 decreased by 18.7% to $3.1 million, from $3.8 million in 2019, principally due to the sale of 51% of our EECP business early in the year, partially offset by an increase in sales in our China operations. Revenues in the IT and professional sales service segments were negatively impacted by the COVID-19 pandemic.
Gross profit for the year ended December 31, 2020 decreased 9.1% to $38.6 million, from $42.4 million in 2019, as a result of the lower sales in our IT and professional sales service segments.
SG&A expenses for the year ended December 31, 2020 decreased $4.0 million or 9.7% to $37.1 million, or 53.0% of revenue, compared with $41.0 million, or 54.3% of revenue, for the same period in 2019. The decrease resulted primarily from a decrease $3.1 million in personnel and travel costs in the professional sales service and IT segments, as well as a decrease in corporate expenses.
For the year ended December 31, 2020, the Company had net income of $358 thousand, compared with a net loss of $382 thousand for the year ended December 31, 2019.
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, and share-based compensation) was $3.6 million for the year ended December 31, 2020 compared to Adjusted EBITDA of $3.5 million for the year ended December 31, 2019.
Net cash provided from operating activities in 2020 was $5.9 million, compared to net cash used in operating activities of $1.3 million in 2019. The increase is principally due to the increase in profitability and the decrease in accounts receivable. Net cash increased to $6.8 million at December 31, 2020, compared to $2.1 million at December 31, 2019. The increase in cash is the net effect of positive cash from operating activities, and proceeds of $3.6 million from a PPP loan, offset by the repayment of $1.2 million of the MedTech note and $1.4 million on our lines of credit. As of April 23, 2020, the Company's net cash was approximately $9.5 million.
Deferred revenue decreased to $17.7 million at December 31, 2020, compared to $19.3 million at December 31, 2019. The decrease is primarily the result of lower order bookings in the professional sales service segment. The deferred revenue will be recognized in the future when the underlying equipment or services are delivered and accepted at the customer site.
About Vaso
Vaso Corporation is a diversified medical technology company with several distinctive but related specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture and sale of proprietary medical devices.
The Company operates through three wholly owned subsidiaries:
VasoTechnology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of Radiology Information System ("RIS"), Picture Archiving and Communication System ("PACS"), and other software solutions from various vendors as well as related services, including implementation, management and support; and NetWolves Network Services LLC, a managed network services provider with an extensive, proprietary service platform to a broad base of customers.
Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments in the USA.
VasoMedical, Inc. manages and coordinates the design, manufacture and sales of proprietary medical equipment and software, as well as operates the Company's overseas assets including China-based subsidiaries.
Additional information is available on the Company's website at www.vasocorporation.com.
Summarized Financial Information
FOR THE THREE MONTHS ENDED FOR THE YEAR ENDED
STATEMENTS OF OPERATIONS
December 31, 2020 December 31, 2019* December 31, 2020 December 31, 2019*
(In thousands)
(Unaudited)
Revenue
$ 18,691 $ 23,721 $ 69,850 $ 75,515
Gross profit
11,076 14,293 38,571 42,432
Operating income
1,302 2,960 772 591
Other income (expense), net
(30 ) (243 ) (415 ) (862 )
Income (loss) before taxes
1,272 2,717 357 (271 )
Income tax benefit (expense)
(96 ) (62 ) 1 (111 )
Net income (loss)
1,176 2,655 358 (382 )
Income tax (benefit) expense
96 62 (1 ) 111
Interest (income) expense, net
129 251 675 962
Depreciation and amortization
601 657 2,462 2,681
Non-cash stock-based compensation
19 18 88 141
Adjusted EBITDA**
$ 2,021 $ 3,643 $ 3,582 $ 3,513
BALANCE SHEETS
December 31, 2020 December 31, 2019*
(In thousands)
Total current assets
$ 22,268 $ 24,059
Total assets
$ 50,376 $ 54,364
Total current liabilities
$ 31,699 $ 33,003
Total stockholders' equity
$ 5,085 $ 4,314
* restated
**Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization and non-cash stock-based compensation
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "optimistic", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the impact of the current COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contact:
Michael J. Beecher
Investor Relations
Phone: 516-997-4600
Email: mbeecher@vasocorporation.com
SOURCE: Vaso Corporation
View source version on accesswire.com:
https://www.accesswire.com/644209/Vaso-Corporation-Announces-Financial-Results-for-Fourth-Quarter-and-Full-Year-of-2020
© Copyright 2021 ACCESSWIRE. All Rights Reserved.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink No Information
Delinquent SEC Reporting
Transfer Agent Verified
AASP name change on the daily list
https://otce.finra.org/otce/dailyList
Summary
Date/Time Event Type Eff/Ex Date/Time Symbol Issue Name Market
04/21/2021 12:15:05 Name/CUSIP Change 04/22/2021 00:00:00 AASP All-American SportPark, Inc. Common Stock Other OTC
Details
Previous Value Current Value
Symbol AASP AASP
Issue Name All-American SportPark, Inc. Common Stock Global Acquisitions Corporation Common Stock
Class
Maturity Date
Market Category Other OTC Other OTC
Unit of Trade 100 100
Regulatory Transaction Fee Flag Yes Yes
Current Value
Daily List Date/Time 04/21/2021 12:15:05
Event Type Name/CUSIP Change
Effective/Ex Date/Time 04/22/2021 00:00:00
Subject to Corporate Action
divy
Corporate actions says shares may be coming but could not give me a definite date, thanks again for the heads up.
I called td and they are checking into it i'll let the board know what they say thanks for the heads up.
I can't find anything that says MTWO shareholders will receive TRKA shares. This from the april 19 s-1
Troika Media Group, Inc. (f/k/a M2 nGage Group, Inc. and f/k/a Roomlinx, Inc., hereinafter the “Company”) was formed in 2003 under the laws of the State of Nevada. On June 12, 2017, the Company entered into and completed a Merger Agreement with Troika Design Group, Inc. (“Troika Merger”). Troika Design Group, Inc. is a strategic brand consultancy with deep expertise in entertainment media, sports, consumer goods and service brands. Prior to the Troika Merger, on October 24, 2016, the Company’s secured lenders took control of all of the equity interests, assets and liabilities of two of the Company’s subsidiaries: M2 nGage Communications Inc., and M2 nGage Inc., and certain operating subsidiaries of the Company also ceased operations. See Business – “Discontinued Operations” below.
My shares show as a cusip # in my tda acct
I sure hope it's worth the wait.
Hi db, i hope all is well with you. I saw that Txic move today but couldn't find any reason for it. Thanks for pointing it out. Might be the right time and place for a substantial move. gltu
CLWY Quarterly Report - Quarterly Report for the Quarter Ended September 30, 2020
https://backend.otcmarkets.com/otcapi/company/financial-report/262781/content
FORM 10-Q
For the quarterly period ended September 30, 2020
https://www.sec.gov/Archives/edgar/data/47307/000143774920023331/crawa20200930_10q.htm
https://otce.finra.org/otce/dailyList
1:100 Reverse Split
Summary
Date/Time Event Type Eff/Ex Date/Time Symbol Issue Name Market
06/10/2020 13:03:42 Reverse Split/CUSIP Change 06/11/2020 00:00:00 MGHL Morgan Group Holding Company Common Stock Other OTC
Comments
In lieu of fractional shares, shareholders shall receive cash in a pro rata amount of the aggregate cash proceeds from the sales of all fractional shares aggregated into whole shares and sold in the open market at the prevailing market price by an agent designated by the corporation.
Details
Previous Value Current Value
Symbol MGHL MGHLD
Issue Name Morgan Group Holding Company Common Stock Morgan Group Holding Company Common Stock
Class
Maturity Date
Market Category Other OTC Other OTC
Unit of Trade 100 100
Regulatory Transaction Fee Flag Yes Yes
Financial Status Indicator
Current Value
Daily List Date/Time 06/10/2020 13:03:42
Event Type Reverse Split/CUSIP Change
Effective/Ex Date/Time 06/11/2020 00:00:00
Subject to Corporate Action CD
Offering Type No Restrictions
Daily List Comment In lieu of fractional shares, shareholders shall receive cash in a pro rata amount of the aggregate cash proceeds from the sales of all fractional shares aggregated into whole shares and sold in the open market at the prevailing market price by an agent designated by the corporation.
Daily List Event Code DA
Forward Split Ratio
Reverse Split Ratio 1:100
Dividend Type Reverse Split
Percentage 0
Cash Amount 0
Declaration Date
Record Date
Payment Date
Payment Method PUS
Qualified Dividend Code
Record ID 40122623
4/27/2020 Audited Financial Statements for the Fiscal Year ending December 31, 2019
https://pm-webapps.s3-us-west-1.amazonaws.com/PropelMedia/investorrelations/Propel+Media+Financial+Statements+2019+-+Final+with+Audit+Opinion.pdf
4/27/2020 Audited Financial Statements for the Fiscal Year ending December 31, 2019
https://pm-webapps.s3-us-west-1.amazonaws.com/PropelMedia/investorrelations/Propel+Media+Financial+Statements+2019+-+Final+with+Audit+Opinion.pdf
Summary
Date/Time Event Type Eff/Ex Date/Time Symbol Issue Name Market
04/07/2020 18:03:22 Cash Dividend Special 04/24/2020 00:00:00 ASNB EKIMAS Corporation Common Stock Other OTC
Details
Previous Value Current Value
Symbol ASNB ASNB
Issue Name EKIMAS Corporation Common Stock EKIMAS Corporation Common Stock
Class
Financial Status Indicator
Market Category Other OTC Other OTC
Current Value
Daily List Date/Time 04/07/2020 18:03:22
Event Type Cash Dividend Special
Daily List Event Code DA
Effective/Ex Date/Time 04/24/2020 00:00:00
Subject to Corporate Action CD
Offering Type No Restrictions
Forward Split Ratio
Reverse Split Ratio
Dividend Type Cash Dividend
Percentage 0
Cash Amount 0.18
Declaration Date
Record Date 04/16/2020 00:00:00
Payment Date 04/23/2020 00:00:00
Payment Method
Qualified Dividend Code
Record ID 40121696
Daily List Comment
I'm not going, an online meeting would be great.
https://otce.finra.org/otce/dailyList
Daily List Events
Summary
Date/Time Event Type Eff/Ex Date/Time Symbol Issue Name Market
04/07/2020 18:03:22 Cash Dividend Special 04/24/2020 00:00:00 ASNB EKIMAS Corporation Common Stock Other OTC
Details
Previous Value Current Value
Symbol ASNB ASNB
Issue Name EKIMAS Corporation Common Stock EKIMAS Corporation Common Stock
Class
Financial Status Indicator
Market Category Other OTC Other OTC
Current Value
Daily List Date/Time 04/07/2020 18:03:22
Event Type Cash Dividend Special
Daily List Event Code DA
Effective/Ex Date/Time 04/24/2020 00:00:00
Subject to Corporate Action CD
Offering Type No Restrictions
Forward Split Ratio
Reverse Split Ratio
Dividend Type Cash Dividend
Percentage 0
Cash Amount 0.18
Declaration Date
Record Date 04/16/2020 00:00:00
Payment Date 04/23/2020 00:00:00
Payment Method
Qualified Dividend Code
Record ID 40121696
Daily List Comment
https://www.otcmarkets.com/stock/ASNB/news/EKIMAS-Corporation-Announces-Special-Cash-Distribution?id=258526
EKIMAS Corporation Announces Special Cash Distribution
Press Release | 04/06/2020
EKIMAS Corporation (OTCQB: “ASNB”), formerly AdvanSource Biomaterials Corporation (the “Company”), which sold substantially all of its assets to Mitsubishi Chemical Performance Polymers, Inc. on January 31, 2020, today announced that the Company’s Board of Directors approved a special cash distribution of $0.18 per share at its April 3, 2020 meeting. The cash distribution is payable on April 23, 2020 to shareholders of record as of April 16, 2020.
About EKIMAS Corporation
EKIMAS Corporation, formerly AdvanSource Biomaterials Corporation (the “Company”), sold substantially all of its assets to Mitsubishi Chemical Performance Polymers, Inc. on January 31, 2020 (the “Closing Date”). As a result, the Company ceased operating as a manufacturer and seller of advanced polymers. Subsequent to the Closing Date, the Company became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. Although certain opportunities have been investigated to determine whether a potential merger opportunity could add value for the benefit of the Company’s shareholders, the Company has not yet entered into any binding arrangements.
Cautionary Note Regarding Forward-Looking Statements
Some of the statements in this release are or may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections presented or implied and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "believe," "expect," "anticipate," "project," "target," "optimistic," "intend," "aim," "will", "may" and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve estimates, expectations and projections and, as a result, are subject to risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially if not substantially from those described in the forward-looking statements. The foregoing listing of risks is not exhaustive. Additional risks and uncertainties are identified and discussed in the Company’s reports filed or to be filed with the SEC, including its Form 10-K for the fiscal year ended March 31, 2019 and Form 10-Q for the fiscal quarter ended December 31, 2019. The Company’s reports, as filed with the SEC, can be found at the SEC’s website at http://www.sec.gov. Forward-looking statements included in this press release speak only as of the date of this press release. The Company undertakes and assumes no obligation, and does not intend, to update the Company’s forward-looking statements, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200406005719/en/
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
OTCQB Member Since 08/2014
OTCQB
Verified Profile 02/2020
Transfer Agent Verified
Hamilton Thorne Announces Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2019
Preliminary Results: Revenues of $35.3 million for the year and $10.8 million for the 4th quarter; Adjusted EBITDA of approximately $7.1 million for the year and $2.2 million for the quarter
Email Print Friendly Share
February 19, 2020 08:20 ET | Source: Hamilton Thorne Ltd.
BEVERLY, Mass. and TORONTO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading global provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today reported preliminary selected unaudited financial results for the fourth quarter and year ended December 31, 2019.
Based on preliminary unaudited results, 2019 revenues increased 21% to a record $35.3 million with adjusted EBITDA for the year of approximately $7.1 million (14.6% year over year growth). Fourth quarter sales increased 34% to $10.8 million, with adjusted EBITDA estimated to increase 27% to approximately $2.2 million. Organic growth on a constant currency basis was approximately 15% for the year and approximately 20% in the fourth quarter, largely driven by sales increases of equipment and consumables. Gross profit margins were approximately 53.8% for the year and 56.4% for the fourth quarter.
David Wolf, President and Chief Executive Officer of Hamilton Thorne Ltd. commented, “2019 was another significant year for Hamilton Thorne with record sales of $35.3 million and adjusted EBITDA of approximately $7.1 million. We continued to invest in sales and support resources in the US and Germany and continued to enhance our operations in order to take better advantage of the cross-selling and marketing synergies between the North American and European-based businesses. We also completed a significant expansion of our product line, geographic coverage and scale when we acquired UK-based Planer Limited in August. We see a significant opportunity to grow revenues from the Planer product line by leveraging our established direct sales channels and expanding the business of other Hamilton Thone brands through additional direct sales capabilities in the UK.”
Commenting on the quarter, Mr. Wolf added, “With sales of $10.8 million and adjusted EBITDA of approximately $2.2 million, this was a record quarter for Hamilton Thorne. We increased our EBITDA margin versus the rest of the year, while continuing to invest in R&D and sales and marketing resources. Sales were positively impacted by the addition of approximately $1.6 million of revenues from the newly acquired Planer business, significant growth in the Company’s laser and image analysis systems business, increased consumables sales, and continued growth of the sale of third-party equipment in the US. Gross profit for the quarter was up versus the balance of the year at approximately 56.4% due to product mix, and relatively flat compared to the prior year’s fourth quarter.”
The Company ended the year with cash on hand of $12.5 million, after investing $6.3 million for the Planer acquisition, versus $13.6 million at December 31, 2018. The year finished with $7.5 million available under existing lines of credit to further support its acquisition program.
OUTLOOK
Mr. Wolf added, “Looking forward into 2020, we expect to see continued growth in our business, driven by substantial growth in our US- and UK-based equipment businesses, augmented by the strong performance of our services and consumables brands worldwide as well as increased sales of our own branded and third-party products in the UK due to our expanding direct sales capabilities. With a number of relatively large dollar, but somewhat lower margin, workstations and full-lab equipment sales in the pipeline for 2020, we may continue to see some variability in gross profit margins from quarter to quarter. We anticipate profit margins for the year to normalize slightly lower than the levels we saw in 2019, given the expected product mix between our own higher margin products and services, and third-party products, as well as the impact of a full year of the somewhat lower gross profit margin Planer business. We will also continue to make investments in personnel, R&D programs and systems to support our growth, with an eye to balancing top-line growth with sustained EBITDA performance in the mid-term and EBITDA expansion over the longer term. Finally, our acquisition program continues to be an important element in our growth plans and we are well positioned to execute on acquisition opportunities.”
Mr. Wolf continued, “We do add one cautionary note relating to the possible effects of the Covid-19 coronavirus. As of now, management is not aware of any sales losses or unusual delays attributable to the spread of this disease; however, we have seen some expanded lead times in the supply of components that we incorporate into our hardware products. Accordingly, while we do not currently anticipate any significant negative effect of our financial results for the first quarter, it is possible that either supply constraints or changes in demand could adversely affect our business and financial results in this or subsequent quarters.”
The financial information contained in this news release is based on management's estimates and is subject to adjustment. The Company expects to release its completed audited financial statements for the year ended December 31, 2019 in mid-April 2020.
All amounts are in US dollars, unless specified otherwise, and results, with the exception of adjusted EBITDA, are expressed in accordance with the International Financial Reporting Standards ("IFRS").
About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
The Company has included earnings before interest, income taxes, depreciation, amortization, share-based compensation expense, changes in fair value of derivatives and identified acquisition costs related to completed transactions (“Adjusted EBITDA”) as a non-IFRS measure, which is used by management as a measure of financial performance. See section entitled “Use of Non-IFRS Measures” and “Results of Operations” in the Company’s Management Discussion and Analysis for the periods covered for further information and a reconciliation of Adjusted EBITDA to Net Income.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.
For more information, please contact:
David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.ltd Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.ltd Glen Akselrod
Bristol Investor Relations
905-326-1888
glen@bristolir.com
nice spread now, .028 x .1278 after 54k vol.hmm
https://www.otcmarkets.com/stock/VODG/news/story?e&id=1516545
Vitro Biopharma 2019 CEO Shareholder Letter: Record Revenues Leading to Further Growth into 2020
GOLDEN, CO / ACCESSWIRE / January 23, 2019 /Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of its 2019 results of operations ended October 31st 2019 and its expansion plans for 2020.
Dear Shareholders,
Our highlights in the year ended October 31st 2019 include:
Expanded revenue generation from InfiniVive-MD™ sales by 365% over 2018. We private label our cosmetic stem cell serum as InfiniVive MD™ in partnership with Jack Zamora MD, a Denver-based cosmetic surgeon for topical cosmetic use in facial applications. We are an FDA-Registered Cosmetic manufacturer for this product. Its sales contributed over $465,000 to our 2019 revenues. The company expects InfiniVive-MD™ to continue to expand its contributions to revenue in 2020. www.infinivivemd.com
Expanded revenue generation from AlloRx™ Stem Cells to DVC Stem in Grand Cayman Island by 290% over 2018 in partnership with Dr. Lou Cona, Medical Director of DVC Stem www.DVCStem.com . We operate with IRB oversight of this trial focused on inflammatory conditions that include Multiple Sclerosis patients; early results indicate safety and symptom remission for prolonged periods by a single treatment.
Gained IRB approval for a new clinical trial in Nassau, Bahamas for "Vitro Biopharma Allogeneic Mesenchymal Stem Cell Therapy for Musculoskeletal Conditions" through our clinical partner, the Medical Pavilion of the Bahamas www.tmp-bahamas.com . Our AlloRx™ Stem Cells will be used to treat osteoarthritis, ligament, tendon and meniscus injury and herniated disc. Patient enrollment is planned for early 2020 and is expected to add to 2020 revenues.
Raised over $120,000 in 5-year lease financing to expand manufacturing facilities. Subsequent to the year end, the company authorized a private Series A Convertible Preferred financing. To date, the company has raised over $500,000 of the series A Convertible Preferred financing the maximum authorized is $1,000,000. The offering is at $0.25 cents per share with ½ 3 year-warrant at $0.50 cents per share and ½ 5 year-warrant at $1.00 per share. The use of proceeds is to engage new auditors and perform 2 years of financial audits in order to go current effective in 2nd to 3rd quarter of 2020. Other use of proceeds is to commence clinical trial operations in the Bahamas, launch our stem cell activation product, STEMulize™ and add a second clean room to our manufacturing facility.
Expanded regulatory compliance to include CLIA and ISO 13485:2016 certifications and maintained our ISO certifications through successful surveillance audit for ISO 9001:2015 and ISO 13485:2016. Vitro Biopharma is cGMP compliant, certified to ISO 9001:2015, ISO 13485:2016, CLIA and is an FDA-registered cosmetic manufacturer. We are committed to compliance with all appropriate regulations and conduct all operations within regulatory guidelines.
Expanded our Advisory Board with the addition of Dr. In Sok Yin https://vitrobiopharma.com/leading-denver-based-orthopedic-surgeon-to-join-vitro-biopharmas-scientific-advisory-board/ to support the development of our US clinical trials starting in 2020. While maintaining and expanding our offshore clinical trials, we plan to extend our trials to the US with the eventual goal of obtaining FDA approval of AlloRx™ Stem Cells for various clinical indications. We plan submission of initial IND applications to the FDA during 2020.
The company began development of new products, STEMulize™ our single capsule format of NutraVivo™ and AlloEX™ Exosomes, our proprietary exosome product derived from AlloRx™ Stem Cells.
Vitro Biopharma announces record revenues for the fiscal year ended October 31st 2019 of $882,376 vs. $523,905 in 2018 based on the expansion of stem cell revenues of $657,745 in 2019 vs. $305,625 in 2018. Total stem cell revenues were up approximately 215% from 2018. This represented 74% of total revenue derived from stem cell revenues in the fiscal year ended October 31st 2019 versus 58% in 2018. Stem cell revenues are expected to comprise over 80% of the company's revenues in 2020. The company also experienced an improvement in its operating loss going from an Operating loss of ($312,871) in 2018 to ($247,423) in 2019.
In the 4th quarter of 2019 the company had record quarterly revenues of $253,090 versus $169,051 in 2018 representing a 50% increase in revenues over the same comparative prior year quarter.
The company experienced a break even cashflow quarter of $7,416 in the fourth quarter ended October 31st 2019.
The company grew consecutive quarterly revenues by 12% from $225,191 in the 3rd quarter of 2019 to $253,090 in the fourth quarter of 2019. This puts the company at an annualized run rate in excess of $1,000,000 going into 2020. In the consecutive quarter from quarter III 2019 to quarter IV 2019 expenses declined slightly from $194,682 to $172,523 representing peak investment in certifications such as ISO:9001; ISO:13485; CLIA and cGMP and FDA consultations. Net income loss between quarter III 2019 of ($91,547) was reduced by 49% to ($46,616) for the quarter ended October 31st 2019.
Subsequent to the year end the company announced a Series A Convertible Preferred private offering.
The Preferred is convertible into the common stock of the company at $0.25 cents per share. The preferred comes with a financing warrant of convertible at ½ share at $0.50 cents a share within 3 years and ½ share at $1.00 per share within 5 years. To date the company has sold $500,000. The company has set a maximum of $1,000,000. Use of proceeds is to engage an auditor and file for current status as well as expand its operations in the Bahamas; commence clinical trials with its patent-pending AlloRx™ Stem Cells in the US market for osteoarthritis, burn therapy and Alzheimer's disease. Additionally, the company will be adding a second clean room to its operations and allocating marketing funds to launch its stem cell activation formulae STEMulize™.
The company saw continued growth with its Cayman Island Partnership with DVC Stem www.dvcstem.com under oversight by IRB Approval # IRCM-SI-181.
The company expanded its new stem cell-based cosmetic product in 2019 with its exclusive partner Infinivive-MD™ operated by Dr. Jack Zamora. Our joint development arrangement contributed over $465,000 to stem cell revenue in 2019 vs $100,000 in 2018. The company expects sales of this new product to increase substantially in 2020. www.jackzamoramd.com www.infinivive.com
Our Stem Cell research products continued to grow providing $207,902 of revenues in 2019 up from $175,729, an 18% year over year increase. The company is experiencing growth in its international customers from prestigious Universities and Medical Institutions. We expect these products to continue to grow as the research community continues to expand its stem cell research and clinical trials of stem cell and cancer regenerative medicine. (Our customer base includes such prestigious names as Harvard University; Cambridge University; The University of France; the Mayo Clinic, Pfizer, amongst others)
The company expended a major effort in 2018/2019 to upgrade our quality systems to the elite status of a biologics manufacturer with ISO certifications. The company is pursuing new international sources of stem cell therapies and many foreign ministries of health require ISO Certification to conduct business in their territories. We expect the cost of being ISO/CLIA certified to be more than offset by new revenues in 2020. The company currently has a number of international business opportunities that we are pursuing.
We continue to expand our intellectual property (IP) that includes a novel US stem cell line patent application for use in numerous regenerative medicine applications including auto-immune disorders such as MS, Lupus, cardiovascular disease, kidney disease, musculoskeletal conditions such as OA and various neurodegenerative disorders. Additional patent applications had been previously filed for treatment of neurological disorders by activation of stem cells within the brain. Our IP now allows proprietary therapies of neurological conditions including Parkinson's disease, Alzheimer's disease and traumatic brain injury (TBI), ASD, etc. Neurological conditions have been under-treated for many years while stem cell therapies offer potentially effective solutions. Hence, we plan commercialization of TBI therapies in 2020. There are more than 1.7 million TBI patients per year in the US while therapy consists of life-saving measures followed by rehabilitation with minimal therapeutic options. Recent advances in stroke recovery by stem cell therapy highlight the regenerative potential of stem cell therapies for neurodegenerative conditions and further support the concept of brain regeneration by stem cell therapy. Our TBI initiative involves stem cell activation therapy and advanced diagnostics including biomarker profiling and brain scans. www.vitrobiopharma.com/blog/
Current management has decided to focus our operational resources to achieve rapid revenue growth & profitability in our high value-added Stem Cell therapies while seeking appropriate strategic alliances and partnerships. Our eventual goal is to be acquired by a larger firm with complimentary resources to those of the Company. The company has four active revenue generating lines of business. The company's advanced stem cell therapies are being utilized offshore and represent preliminary data to drive US-based clinical trials for such major diseases as Multiple Sclerosis, stroke, PD using our AlloRx™ Stem Cells. The company is building offshore revenue support while simultaneously building its clinical trial data base of treated diseases, such as MS. Each disease represents billion-dollar market potential for our AlloRx™ Stem Cells. We have co-developed with Dr. Jack Zamora a topical cosmetic product, InfiniVive-MD that now drives 50% of our revenue. The InfiniVive market is the billion-dollar cosmetic salon industry. We are in discussions through our partner with large US-based cosmetic equipment manufacturers that reach thousands of salons across the US market. Complementing our clinical grade AlloRx™ Stem Cells, the company has developed a patent-pending nutraceutical product that is a natural stem cell activation formula that can be used stand alone or enhance the results obtained when using our clinical grade AlloRx™ Stem Cells. The company is in discussions regarding partnerships to take its patent pending formulation to market. The company's fourth revenue stream is its core business of research stem cell/cancer products that continues to grow at 20% per annum and provides a base cashflow to support the Research and Development activities of the company.
The company is also in the process of engaging new auditors for the purpose of auditing the companies last two years of results and reporting to the SEC to become current and actively list the company for fully authorized trading. The company is also considering a numberof acquisition opportunities to grow the company where the acquisition is strategically aligned with the company.
In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 25-years' experience in the development and commercialization of stem cell products for research, recognized by a "Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology" www.vitrobiopharma.com/frost-sullivan and a growing track record of successful translation to therapy. The successes of stem cell therapies in treatment of conditions without viable treatment options continues to drive growth of regenerative medicine as an alternative to traditional medicine based on pharmaceutical & surgical approaches. We plan to leverage our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence while operating in full compliance with the FDA and other applicable regulations.
Sincerely yours,
James R. Musick, PhD.
President, CEO & Chairman of the Board
Forward-Looking Statements
Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
John Evans
(303) 601-7855
john@vitrobiopharma.com
Vitro Diagnostics, Inc.Year Ended Oct 31st.Income Statement
2019 2018
Stem Cell Therapies and applications
657,745 305,625
Stem Cell Products
207,902 175,729
Other Services
16,729 42,551
Total Revenues
882,376 523,905
COGS
257,901 150,596
Gross Profit
624,475 71% 373,309 71%
SGA Expenses
220,550 133,335
Office Expenses
47,661 47,961
Consulting,Accounting,Legal and Banking Fees
220,786 124,470
Laboratory R&D & Quality Control
194,788 128,438
Total Operating Expenses
683,785 434,204
Net Operating Profit (Loss)
(59,309) (60,895)
Non Cash Depreciation and Amortization
(58,465 ) (45,168 )
Non Cash Stock for Services
- (80,000 )
Non Cash Interest on Secured Notes Payable
(93,189 ) (32,707 )
Non Cash Interest on Shareholder Debt
(36,459 ) (94,101 )
Net Income (Loss)
(247,423) (312,871)
The company provides its financial information for investor information purposes only. The results published however are not audited or necessarily SEC and/or GAAP compliant.
Vitro Diagnostics, Inc.Year Ended Oct 31st.Balance Sheet
2019 2018
ASSETS
Cash
118,624 392,996
Accounts Receivable
178,172 97,826
Inventory
49,220 23,017
Notes Receivable and Prepaids
39,000 111,500
Current Assets
385,015 625,339
-
Fixed Assets
236,329 166,287
Intangible and other Assets
34,968 34,729
Total Assets
656,312 826,355
LIABILITIES
Trade Accounts Payable
57,778 85,538
Bank Credit Cards
34,229 49,820
Capital Lease Obligaitons
50,523 28,274
Current Liabiities
142,529 163,632
Secured Convertible Notes
987,104 891,416
Capital Lease Obligations
145,445 65,972
Shareholder Accrued Comp. Payable
1,221,958 1,205,957
Shareholder Debts Payable
628,339 652,881
Long Term Liabilities
2,982,847 2,816,226
Total Liabilities
3,125,376 2,979,858
SHAREHOLDERS EQUITY
Common Stock
22,651 22,651
Paid in Capital
6,633,785 6,697,785
Retained Earnings
(8,878,076 ) (8,561,067 )
Net Income
(247,423 ) (312,872 )
Total Equity
(2,469,064) (2,153,503)
TOTAL LIABILITES AND EQUITY
656,312 826,355
The company provides its financial information for investor information purposes only. The results published however are not audited or necessarily SEC and/or GAAP compliant.
Vitro Diagnostics, Inc.Year Ended Oct 31st.Statement of Cashflows
2019
Net Loss ended Oct. 31st;
(247,423)
Non Cash Depreciation and Amortization
58,465
Decrease in current and other Assets
(303,083 )
Increase in Current and other current Liabilities
50,753
Net cash used in operations year ended Oct. 31st 2019
(441,288)
Cashflows from Investing Activities during the Quarter
Equipment and Patent Expenditures
(78,600 )
Equipmment Financing
115,868
Increase in Notes Payable
Non Cash Secured Note Interest
93,189
Non Cash Shareholder Note Interest
36,459
Net Cash provided by Financing Activities during the Quarter
166,916
Net Increase (Decrease) in Cash for the year ended Oct. 31st 2019
(274,372)
Cash Beginning of the Year Nov, 1st 2018
392,996
Cash Year ended Oct, 31st 2019
118,624
Vitro Diagnostics, Inc.Year Ended Oct 31st.Statement of Changes in Shareholders Equity
Par Paid
Shares Value in Capital
Balance Nov.1st 2019
46,094,200 22,652 6,697,785
Equity converted by an affiliate
(213,333 ) (64,001 )
Balance Oct. 31st 2019
45,880,867 22,652 6,633,784
The fully diluted Shares outstanding consists of;
Currently issued shares
45,880,867
Secured Convertible Notes ($962,837 at $0.05 cents/share)
19,256,740
Management Stock Options vested at $0.05cents/share
4,120,000
69,257,607
The company provides its financial information for investor information purposes only. The results published however are not audited or necessarily SEC and/or GAAP compliant.
Vitro Diagnostics, Inc.
QIV Oct. 31st
Income Statement
2019 2018
Stem Cell Therapies and applications
181,171 80,841
Stem Cell Products
70,171 58,138
Other Services
1,748 30,072
Total Revenues
253,090 169,051
COGS
73,151 56,951
Gross Profit
179,939 71% 112,100 71%
SGA Expenses
59,601 36,605
Office Expenses
14,378 19,932
Consulting,Accounting,Legal and Banking Fees
53,518 32,745
Laboratory R&D & Quality Control
45,027 20,908
Total Operating Expenses
172,523 110,190
Net Operating Profit (Loss)
7,416 1,910
Non Cash Depreciation and Amortization
(20,433 ) (13,735 )
Non Cash Stock for Services
- -
Non Cash Interest on Secured Notes Payable
(24,267 ) (15,566 )
Non Cash Interest on Shareholder Debt
(9,332 ) (9,362 )
Net Income (Loss)
(46,616 ) (36,753 )
The company provides its financial information for investor information purposes only. The results published however are not audited or necessarily SEC and/or GAAP compliant.
Vitro Diagnostics, Inc.
QIV Oct. 31st and QIII July 31st
Income Statement
2019 2019
Stem Cell Therapies and applications
181,171 175,533
Stem Cell Products
70,171 49,658
Other Services
1,748 -
Total Revenues
253,090 225,191
COGS
73,151 75,622
Gross Profit
179,939 71% 149,569 71%
SGA Expenses
59,601 77,387
Office Expenses
14,378 12,524
Consulting,Accounting,Legal and Banking Fees
53,518 66,035
Laboratory R&D & Quality Control
45,027 38,736
Total Operating Expenses
172,523 194,682
Net Operating Profit (Loss)
7,416 (45,113 )
Non Cash Depreciation and Amortization
(20,433 ) (13,627 )
Non Cash Stock for Services
- -
Non Cash Interest on Secured Notes Payable
(24,267 ) (23,614 )
Non Cash Interest on Shareholder Debt
(9,332 ) (9,193 )
Net Income (Loss)
(46,616 ) (91,547 )
The company provides its financial information for investor information purposes only. The results published however are not audited or necessarily SEC and/or GAAP compliant.
SOURCE: Vitro Diagnostics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/573899/Vitro-Biopharma-2019-CEO-Shareholder-Letter-Record-Revenues-Leading-to-Further-Growth-into-2020
© Copyright 2020 ACCESSWIRE. All Rights Reserved.
https://www.otcmarkets.com/stock/STKR/news/story?e&id=1512186
ProPhotonix Limited Announces Trading Update 2019
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain
-Improved 2H order bookings and shipments
SALEM, NH / ACCESSWIRE / January 16, 2020 / ProPhotonix Limited (LSE:PPIX)(OTC PINK:STKR), a leading technology designer and manufacturer of LED illumination systems and laser diode modules, with operations in Ireland and the United Kingdom, is pleased to announce a trading update for the year ended December 31, 2019.
Trading conditions improved in the second half of 2019 as compared to the first half 2019 with orders placed approximating $9.3 million (1H 2019: $7.1 million), an increase of 30%, and revenue recognized of approximately $7.8 million (1H 2019: $7.1 million), an increase of 9%. Importantly, much of this increase was from the Group's larger and more important customers, albeit not yet having recovered to 2018 run-rate levels. This second half performance resulted in orders placed for the full year totaling approximately $16.5 million (2018: $16.1 million) and revenue recognized of approximately $14.9 million (2018: $16.4 million), in line with previous guidance.
Tim Losik, CEO, commented:
"The Board is pleased with the rebound in business in the second half of the year following a resumption of orders from the Group's largest laser module customer and increases in orders from and shipments to other major customers. Despite this improved customer activity, there remain a number of key accounts who have yet to resume their activity to the levels in 2018. However, following recent discussions with many of these other customers, the outlook for 2020 is more positive than 2019.
"Our strategy, to support our significant OEM customer base and to make continued investments in new product introductions, continues to be a priority for the Board. We continue to invest in production and technical capability as we take on new customers and develop products. These investments, which will occur in advance of realized revenue, will allow us to complete the production build out necessary for OEM and UV LED products."
Enquiries:
ProPhotonix Limited Tel: +1 603 893 8778
Tim Losik, President and CEO Email: ir@prophotonix.com
Cantor Fitzgerald Europe Tel: +44 (0)207 894 7000
(Nominated Adviser and Broker)
David Foreman
Luke Philippou
About ProPhotonix
ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of LED illumination systems and laser diode modules for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio, Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com.
Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ProPhotonix Limited
View source version on accesswire.com:
https://www.accesswire.com/573227/ProPhotonix-Limited-Announces-Trading-Update-2019
© Copyright 2020 ACCESSWIRE. All Rights Reserved.
same here
Thanks for posting that, I was wondering why it had perked up recently
Energy Hunter Resources, Inc. Completes All-Stock Transaction with Home Treasure Finders, Inc.
DENVER--(BUSINESS WIRE)-- Energy Hunter Resources, Inc., a privately held, Dallas, Texas-based energy producer, announced today that it has closed on an all-stock transaction with Home Treasure Finders, Inc. (OTCPK: HMTF), a real estate company based in Denver, Colorado, that leases warehouse space to hemp seed growers. Under the terms of the transaction, Home Treasure Finders will obtain approximately 91% of the currently outstanding shares of Energy Hunter Resources, and Energy Hunter will become a subsidiary of Home Treasure Finders. In exchange, the transferring shareholders of Energy Hunter Resources will receive 6,328,948 shares of fully voting Series A Convertible Preferred Stock, which equates to 88% of the ownership of Home Treasure Finders on a fully diluted, as-converted basis. Home Treasure Finders has filed an application with FINRA to change its name to Generation Hemp, Inc. Pending final approval from FINRA, which management anticipates receiving within 10 days of closing, a press release will be issued formally announcing the new name and ticker symbol.
As part of the transaction, Corey Wiegand, who has been the President and sole Director of Home Treasure Finders, Inc. since its founding, has resigned from these positions. He plans to focus his business career in the real estate industry. Gary C. Evans, current Chairman and Chief Executive Officer of Energy Hunter, has taken the helm of the combined entity as Chairman of the Board of Directors and Chief Executive Officer. Mr. Evans will begin immediate execution on all pending and planned initiatives.
Mr. Evans commented, “Today’s announcement solidifies our long anticipated transition to becoming a pure-play, publicly traded U.S. Hemp company. In addition to Generation Hemp’s Denver, Colorado-based real estate asset under lease to a hemp seed company, our newly combined company will seek to explore various acquisition opportunities throughout the seed-to-sale value chain within the hemp industry. We believe that the new management team’s extensive acquisitive history and capital markets experience, combined with its knowledge within this exciting sector, provide us with key competitive advantages for the consolidation opportunities we see ahead. At the same time, we will pursue an eventual uplist to the NASDAQ Capital Markets Exchange, which will further position us as one of the few pure-play, publicly traded U.S. Hemp companies on a major U.S. stock exchange.”
Mr. Evans continued, “In conjunction with the divestiture of our existing oil and gas assets, which we anticipate to be finalized during fiscal 2020, the Company will begin execution on hemp sector acquisitions that have been thoroughly vetted over the past several months. Our shareholders should be clear that we have no plans to participate in any form within the marijuana sector. We believe that opportunities in the hemp sector are plentiful and that the benefits associated with cannabinoids have the potential to revolutionize entire industries, including, but not limited to, nutrition, wellness, sleep, food, healthcare and beauty. Projected growth of CBD sales in the U.S. are estimated to grow to over $2.7 billion in 2020 and to more than $8 billion by 2025.
“While many people are becoming familiar with the benefits associated with CBD, CBG, CBN and other cannabinoids, we also see significant opportunities and upside potential in the industrial hemp sector. Industrial hemp applications have already begun in some of our country’s largest industries, including lumber, textiles, plastics, automotive, home-building/installation and more. As mentioned, the Company is exploring a number of shareholder-friendly acquisition opportunities throughout the industrial and non-industrial hemp value chain.”
Corey Wiegand, founder and outgoing President of Home Treasure Finder’s Inc., added, “When I founded Home Treasure Finders in 2008 I had a vision to build a successful real estate company. This vision took us down many paths, from multi-family projects to single-family home transactions to commercial real estate ventures. But regardless of the project, the endeavor was always a labor of love. Therefore, while my decision to merge Home Treasure Finders with Energy Hunter Resources, soon to be renamed Generation Hemp, Inc., was not an easy one, I believe that it is in the best interest of our shareholders. I thank all of our clients and shareholders for their support over the years and look forward to watching the combined company grow and prosper.”
Transaction Highlights
Home Treasure Finders, Inc. completes previously announced stock-for-stock transaction with Energy Hunter Resources, Inc.
The transferring Energy Hunter Resources’ shareholders now control 88% of the voting securities of HMTF on a fully diluted, as-converted basis.
The transferring Energy Hunter Resources’ shareholders will receive a share of HMTF fully voting Series A Convertible Preferred Stock for each share of Energy Hunter common stock they own, convertible into 15.7 shares of HMTF’s common stock. The Series A Convertible Preferred votes on an as-converted basis.
HMTF has affected a corporate name change to Generation Hemp, Inc.
Generation Hemp, Inc., subsequent to divesting all of its oil and gas properties, which is anticipated to take place in fiscal 2020, plans to operate as a pure-play, hemp-only company.
Corey Wiegand, President of Home Treasure Finders, Inc., has resigned as President and sole Director of the Company to focus his ongoing endeavors in the real estate industry.
Gary C. Evans, Chairman and Chief Executive Officer of Energy Hunter Resources, has taken over those roles at Generation Hemp, Inc. as of the closing.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as “believes”, “expects”, “anticipates”, “intends”, “plans”, “estimates”,” projects”, “forecasts”, “proposes”, “should”, “likely” or similar expressions, indicates a forward-looking statement. These statements and all the projections in this press release are subject to risks and uncertainties and are based on the beliefs and assumptions of management, and information currently available to management. The actual results could differ materially from a conclusion, forecast or projection in the forward-looking information. The identification in this press release of factors that may affect the company’s future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive.
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20191202005264r1&sid=acqr7&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005264/en/
Anthony D. Andora
Generation Hemp, Inc.
Phone: 720-317-8927
Email: Aandora@GenHempInc.com
Source: Generation Hemp, Inc.
© Copyright Business Wire 2019
Same here Dream, we'll own the whole company :)
15,800
yw thanks for GRVY!
fwiw I scheduled an appointment with tda tech support help me set up my thinkorswim platform. It is overwhelming. They were excellent and it now works much better for me than trade architect ever did.